- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
FDA pipeline preview, November 2007
The latest FDA action (through November 2007) related to anecortave depot suspension (Retaane), lamotrigine extended-release (Lamictal XR), pramlintide injection (Symlin), frovatriptan (Frova), lumiracoxib (Prexige), PI-88, C1 inhibitor (Cinryze), Etravirine, IPI-504, Parathyroid hormone (rDNA origin) for injection (Preos), and pafuramidine
Key Points
Approvable designations
• Anecortave depot suspension (Retaane, Alcon) for the treatment of wet age-related macular degeneration
• Lamotrigine extended-release (Lamictal XR, GlaxoSmithKline) for the treatment of epilepsy
• Pramlintide injection (Symlin, Amylin) for use with basal insulin (without mealtime insulin) in patients with type 2 diabetes who have not achieved desired glucose control
• Frovatriptan (Frova, Endo/Vernalis) for the short-term prevention of menstrual migraine
• Lumiracoxib (Prexige, Novartis) for the once-daily treatment of osteoarthritic pain
Fast-track designation
• PI-88 (Progen) for the prevention of tumor recurrence following curative liver resection in patients with hepatocellular carcinoma
Priority review
• C1 inhibitor (Cinryze, Lev) for the acute treatment of hereditary angioedema
• Etravirine (TMC125, Tibotec) in combination with other antiretroviral agents for the treatment of HIV-1 in adult treatment-experienced patients
Orphan drug designations
• IPI-504 (Infinity/MedImmune) for the treatment of gastrointestinal stromal tumors
• Parathyroid hormone (rDNA origin) for injection (Preos, NPS) for the treatment of hypoparathyroidism
• Pafuramidine (DB289, Immtech) for the treatment of human African trypanosomiasis (African sleeping sickness)
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
